These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 27021055)

  • 61. Visual Hallucinations with Methylphenidate and Acetaminophen in Combination.
    Hergüner S; Özayhan HY
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):598-9. PubMed ID: 26222326
    [No Abstract]   [Full Text] [Related]  

  • 62. Methylphenidate for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.
    Storebø OJ; Simonsen E; Gluud C
    JAMA; 2016 May; 315(18):2009-10. PubMed ID: 27163989
    [TBL] [Abstract][Full Text] [Related]  

  • 63. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.
    Groenman AP; Schweren LJ; Dietrich A; Hoekstra PJ
    Expert Opin Drug Saf; 2017 Apr; 16(4):455-464. PubMed ID: 28277842
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Reboxetine use in the treatment of attention-deficit/hyperactivity disorder.
    Cak HT; Cetin FC
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):803-4. PubMed ID: 17201625
    [No Abstract]   [Full Text] [Related]  

  • 66. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Use of methylphenidate in adults with attention deficit disorder with hyperactivity].
    Gauillard J; Castelnau C; Vacheron-Trystram MN; Cheref S; Caroli F
    Encephale; 1997; 23(4):251-6. PubMed ID: 9417389
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [The practice and problem of therapeutic agents for AD/HD].
    Tanaka H; Miyajima T
    No To Hattatsu; 2010 May; 42(3):213-6. PubMed ID: 23858580
    [No Abstract]   [Full Text] [Related]  

  • 69. Long-term effects of ADHD medication on adult height: results from the NESARC.
    Peyre H; Hoertel N; Cortese S; Acquaviva E; Limosin F; Delorme R
    J Clin Psychiatry; 2013 Nov; 74(11):1123-4. PubMed ID: 24330902
    [No Abstract]   [Full Text] [Related]  

  • 70. Methylphenidate an effective treatment for ADHD?
    McDougle CJ
    J Autism Dev Disord; 2004 Oct; 34(5):593-4. PubMed ID: 15628613
    [No Abstract]   [Full Text] [Related]  

  • 71. OROS methylphenidate-induced skin eruptions.
    Coskun M; Tutkunkardas MD; Zoroglu S
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):593-4. PubMed ID: 19877987
    [No Abstract]   [Full Text] [Related]  

  • 72. [Ritalin for better or worse[Editorial]].
    Halldórsson M
    Laeknabladid; 2010 Sep; 96(9):519. PubMed ID: 20820066
    [No Abstract]   [Full Text] [Related]  

  • 73. Cotempla XR-ODT--another long-acting methylphenidate for ADHD.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):183-185. PubMed ID: 29125594
    [No Abstract]   [Full Text] [Related]  

  • 74. Improving decision making in the treatment of ADHD.
    Vitiello B
    Am J Psychiatry; 2008 Jun; 165(6):666-7. PubMed ID: 18519529
    [No Abstract]   [Full Text] [Related]  

  • 75. Quillivant XR--an extended release oral suspension of methylphenidate.
    Med Lett Drugs Ther; 2013 Feb; 55(1409):10-1. PubMed ID: 23381227
    [No Abstract]   [Full Text] [Related]  

  • 76. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder.
    Fone KC; Nutt DJ
    Curr Opin Pharmacol; 2005 Feb; 5(1):87-93. PubMed ID: 15661631
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comments on 'Cytogenetic effects in children treated with methylphenidate' by El-Zein et al.
    Preston RJ; Kollins SH; Swanson JM; Greenhill LL; Wigal T; Elliott GR; Vitiello B
    Cancer Lett; 2005 Dec; 230(2):292-4. PubMed ID: 16019134
    [No Abstract]   [Full Text] [Related]  

  • 78. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
    Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
    Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Status epilepticus associated with the administration of long-acting methylphenidate in a 7-year-old girl.
    Goetz M; Surman CB; Mlynarova E; Krsek P
    J Clin Psychopharmacol; 2012 Apr; 32(2):300-2. PubMed ID: 22388167
    [No Abstract]   [Full Text] [Related]  

  • 80. Forty years of methylphenidate treatment in Attention-Deficit/ Hyperactivity Disorder.
    Conners CK
    J Atten Disord; 2002; 6 Suppl 1():S17-30. PubMed ID: 12685516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.